Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?

Author： Walter Thomas   Scoazec Jean-Yves   Couderc Christophe   Forestier Julien   Roche Colette   Chayvialle Jean-Alain   Lombard-Bohas Catherine  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.50, Iss.5, 2011-06, pp. : 731-732

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mechanisms of mTOR inhibitor resistance in cancer therapy

By Carew Jennifer  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 17-27

Springer Publishing Company

Access to resources Recommend Favorite

Role of mTOR inhibitor in cholangiocarcinoma cell progression

By        

Oncology Letters, Vol. 7, Iss. 3, 2014-01 ,pp. : 854-860

Spandidos Publications

Access to resources Recommend Favorite

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

By Pal Sumanta  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 5-16

Springer Publishing Company

Access to resources Recommend Favorite

The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy

By                

International Journal of Oncology, Vol. 41, Iss. 4, 2012-01 ,pp. : 1381-1386

Spandidos Publications

Access to resources Recommend Favorite

Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk

By Shu Xiang   Lin Jie   Wood Christopher G.   Tannir Nizar M.   Wu Xifeng  

Journal of the National Cancer Institute, Vol. 105, Iss. 6, 2013-03 ,pp. : 424-432

Oxford University Press

Access to resources Recommend Favorite